121 related articles for article (PubMed ID: 38158149)
1. Mitochondrial Mechanisms in Temozolomide Resistance: Unraveling the Complex Interplay and Therapeutic Strategies in Glioblastoma.
Li HY; Feng YH; Lin CL; Hsu TI
Mitochondrion; 2024 Mar; 75():101836. PubMed ID: 38158149
[TBL] [Abstract][Full Text] [Related]
2. Reprogramming of arachidonate metabolism confers temozolomide resistance to glioblastoma through enhancing mitochondrial activity in fatty acid oxidation.
Tsai YT; Lo WL; Chen PY; Ko CY; Chuang JY; Kao TJ; Yang WB; Chang KY; Hung CY; Kikkawa U; Chang WC; Hsu TI
J Biomed Sci; 2022 Mar; 29(1):21. PubMed ID: 35337344
[TBL] [Abstract][Full Text] [Related]
3. RUNX1 (RUNX family transcription factor 1), a target of microRNA miR-128-3p, promotes temozolomide resistance in glioblastoma multiform by upregulating multidrug resistance-associated protein 1 (MRP1).
Xu J; Song J; Xiao M; Wang C; Zhang Q; Yuan X; Tian S
Bioengineered; 2021 Dec; 12(2):11768-11781. PubMed ID: 34895074
[TBL] [Abstract][Full Text] [Related]
4. Activated TRPA1 plays a therapeutic role in TMZ resistance in glioblastoma by altering mitochondrial dynamics.
Chen H; Li C; Hu H; Zhang B
BMC Mol Cell Biol; 2022 Aug; 23(1):38. PubMed ID: 35982414
[TBL] [Abstract][Full Text] [Related]
5. Dysregulated lipid metabolism in TMZ-resistant glioblastoma: pathways, proteins, metabolites and therapeutic opportunities.
Kao TJ; Lin CL; Yang WB; Li HY; Hsu TI
Lipids Health Dis; 2023 Aug; 22(1):114. PubMed ID: 37537607
[TBL] [Abstract][Full Text] [Related]
6. Intracellular Redox-Balance Involvement in Temozolomide Resistance-Related Molecular Mechanisms in Glioblastoma.
Lo Dico A; Salvatore D; Martelli C; Ronchi D; Diceglie C; Lucignani G; Ottobrini L
Cells; 2019 Oct; 8(11):. PubMed ID: 31653091
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation.
Liang H; Chen Z; Sun L
Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274
[TBL] [Abstract][Full Text] [Related]
8. Extracellular vesicles carry miR-27a-3p to promote drug resistance of glioblastoma to temozolomide by targeting BTG2.
Chen L; Li Z; Hu S; Deng Q; Hao P; Guo S
Cancer Chemother Pharmacol; 2022 Feb; 89(2):217-229. PubMed ID: 35039898
[TBL] [Abstract][Full Text] [Related]
9. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation.
Su IC; Su YK; Setiawan SA; Yadav VK; Fong IH; Yeh CT; Lin CM; Liu HW
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175412
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
[TBL] [Abstract][Full Text] [Related]
11. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
12. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
Kim SS; Rait A; Kim E; Pirollo KF; Chang EH
Nanomedicine; 2015 Feb; 11(2):301-11. PubMed ID: 25240597
[TBL] [Abstract][Full Text] [Related]
13. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
14. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
15. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
Jin L; Kiang KM; Cheng SY; Leung GK
Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658
[TBL] [Abstract][Full Text] [Related]
17. Diterpenoid honatisine overcomes temozolomide resistance in glioblastoma by inducing mitonuclear protein imbalance through disruption of TFAM-mediated mtDNA transcription.
Li Z; Sai K; Ma G; Chen F; Xu X; Chen L; Wang S; Li W; Huang G; Cui P
Phytomedicine; 2024 Jun; 128():155328. PubMed ID: 38522316
[TBL] [Abstract][Full Text] [Related]
18. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y
EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.
Chen JC; Lee IN; Huang C; Wu YP; Chung CY; Lee MH; Lin MH; Yang JT
BMC Cancer; 2019 Aug; 19(1):756. PubMed ID: 31370819
[TBL] [Abstract][Full Text] [Related]
20. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
